Alzheimer’s disease (AD), the most common neurodegenerative disease, is increasingly being proposed as ‘type 3 diabetes’ because of the characteristic inability of brain neurons to respond to insulin in patients with AD, coupled with the accumulation of tau proteins, formation of neurofibrillary tangles (NFTs), enhanced neuro-inflammation, and neurodegeneration [4,5]. This evidence concerns the gene MAPT and Alzheimer disease.